Month: February 2011

Trials were conducted across a range of therapeutic areas, study designs.

Avantra Biosciences announced its first shipments of the new Q400 Biomarker Workstation (pictured) and the innovative Angio Qx BioChip Immunoassay.

Three-year contract is purportedly worth $450 million.

Study designed to evaluate side effect, safety advantages compared to equi-analgesic doses of morphine, oxycodone.

New facility set to open this spring builds on GE’s agreement with Ontario government and the company’s commitment to improve cost, quality and access to health care.